Abstract
Ravulizumab (ULTOMIRIS®) is the first long-acting complement C5 inhibitor (administered intravenously every 8 weeks) to be approved in several countries globally, for adults with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody-positive (AChR Ab+). In the phase III CHAMPION MG trial, intravenous ravulizumab was associated with statistically significant improvements in the MG-Activities of Daily Living scale at week 26 of treatment compared with placebo in adults with AChR Ab+ gMG. Improvements in the Quantitative MG scale total score were also statistically significantly higher in ravulizumab than placebo recipients. These improvements were sustained to week 26 of treatment. Ravulizumab was generally well tolerated; the most common treatment-emergent adverse events were headache, diarrhoea and nausea. Efficacy and tolerability data for up to 1 year from the ongoing open-label extension phase are consistent with those from the randomized, placebo-controlled phase; further results are awaited with interest. Thus, ravulizumab is an efficacious, generally well tolerated and convenient treatment option in adults with AChR Ab+ gMG, expanding the options available for gMG management.
Plain Language Summary
Generalised myasthenia gravis (gMG) is a rare chronic condition that affects the muscles, making them become abnormally tired and weak after use. Prevalence can vary (5.3–35 per 100,000 people) and is steadily rising. Management of gMG can involve modifying or suppressing the immune system, symptom management and/or surgical removal of the thymus gland. Complement C5 inhibitors are another treatment option for patients with gMG. Ravulizumab (ULTOMIRIS®) is the first long-acting complement C5 inhibitor (administered intravenously every 8 weeks) to be approved in several countries globally for the treatment of adults with gMG who are anti-acetylcholine receptor antibody-positive (AChR Ab+). Ravulizumab is associated with long-lasting improvements in activities of daily living and disease status in adults with AChR Ab+ gMG, as demonstrated in a phase III clinical trial. In this trial, ravulizumab was generally well tolerated; headache, diarrhoea and nausea were the most common adverse events. Although there is a potential risk for adverse reactions with ravulizumab treatment, including serious meningococcal infections, other infections and infusion-related reactions, no meningococcal infections occurred and the incidence of infusion-related reactions was low in patients with gMG. The efficacy and tolerability of ravulizumab were sustained for up to 1 year of treatment; further results are awaited with interest. Thus, ravulizumab is an efficacious, generally well tolerated and convenient treatment option in adults with AChR Ab+ gMG, expanding the options available for gMG management.
Similar content being viewed by others
References
Vu T, Meisel A, Mantegazza R, et al. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. 2022;1(5):1–12.
Menon D, Bril V. Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals. Drugs. 2022;82(8):865–87.
Farrugia ME, Goodfellow JA. A practical approach to managing patients with myasthenia gravis-opinions and a review of the literature. Front Neurol. 2020;11:604.
Vanoli F, Mantegazza R. Antibody therapies in autoimmune neuromuscular junction disorders: approach to myasthenic crisis and chronic management. Neurotherapeutics. 2022;19(3):897–910.
Verschuuren JJGM, Palace J, Murai H, et al. Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21(2):189–202.
Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis. Neurology. 2021;96(3):114–22.
US Food & Drug Administration. SOLIRIS® (eculizumab) injection, for intravenous use: US prescribing information. 2020. https://www.accessdata.fda.gov. Accessed 3 Apr 2023.
European Medicines Agency. Soliris (eculizumab): EU summary of product characteristics. 2022. https://www.ema.europa.eu. Accessed 3 Apr 2023.
Sheridan D, Yu ZX, Zhang Y, et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS ONE. 2018;13(4): e0195909.
Alexion Pharmaceuticals Inc. ULTOMIRIS (ravulizumab-cwvz) injection, for intravenous use: US prescribing information. 2022. https://www.accessdata.fda.gov. Accessed 3 Apr 2023.
European Medicines Agency. Ultomiris (ravulizumab): EU summary of product characteristics. 2022. https://www.ema.europa.eu. Accessed 3 Apr 2023.
Pharmaceuticals and Medical Devices Agency. ULTOMIRIS intravenous infusion 300mg / ULTOMIRIS HI intravenous infusion 300mg/3mL/ULTOMIRIS HI intravenous infusion 1100mg/11mL: Japanese prescribing information. 2022. https://www.pmda.go.jp. Accessed 3 Apr 2023.
Syed YY. Ravulizumab: a review in atypical haemolytic uraemic syndrome. Drugs. 2021;81(5):587–94.
McKeage K, Lyseng-Williamson KA. Ravulizumab in paroxysmal nocturnal hemoglobinuria: a profile of its use. Drugs Ther Perspect. 2019;35(9):405–12.
Sahelijo L, Mujeebuddin A, Mitchell D, et al. First in human single-ascending dose study: safety, biomarker, pharmacokinetics and exposure-response relationships of ALXN1210, a humanized monoclonal antibody to C5, with marked half-life extension and potential for significantly longer dosing intervals. Blood. 2015;126(23):4777.
Vu T, Ortiz S, Katsuno M, et al. Pharmacokinetics and pharmacodynamics of ravulizumab in adults with generalized myasthenia gravis: results from the phase 3 CHAMPION MG study (abstract no. P3-1.002) Neurology. 2022;98(Suppl. 18):850.
Vu T, Meisel A, Mantegazza R, et al. Long-term efficacy and safety of ravulizumab in generalized myasthenia gravis: phase 3 CHAMPION MG study open-label extension [abstract]. Clin Exp Neuroimmunol. 2023;14(1):69–73.
Uzawa A, Juel V, Vu T, et al. Efficacy of ravulizumab across sex and age subgroups of patients with generalized myasthenia gravis: a post hoc analysis of the CHAMPION MG study [abstract]. Clin Exp Neuroimmunol. 2023;14(1):69–73.
Suzuki S, Howard JF Jr, Vu T, et al. Ravulizumab efficacy in generalized myasthenia gravis by the time from diagnosis [abstract]. Clin Exp Neuroimmunol. 2023;14(1):69–73.
Vu T, Meisel A, Mantegazza R, et al. Long-term efficacy and safety of ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. Muscle Nerve. 2022;65(Suppl. 1):S2–3.
Lehnerer S, Jacobi J, Schilling R, et al. Burden of disease in myasthenia gravis: taking the patient’s perspective. J Neurol. 2021;269(6):3050–63.
Vitturi BK, Pellegrinelli A, Valerio BCO. Medication adherence in patients with myasthenia gravis in Brazil: a cross-sectional study. Acta Neurol Belg. 2019;120(1):83–9.
Parthan A, Johnston K, Govindarajan R. Economic impact of treating generalized myasthenia gravis with ravulizumab vs eculizumab: US payer perspective [abstract no. G45]. J Manag Care Spec Pharm. 2022;28(Suppl. 3-a):S53–4.
Acknowledgements
During the peer review process, Alexion, AstraZeneca Rare Disease, was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest
Connie Kang is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability
Not applicable.
Additional information
The manuscript was reviewed by: M. Alotaibi, Department of Physical Therapy, Northern Border University, Arar, Saudi Arabia; F. Brigo, Department of Neurology, Hospital of Merano (SABES-ASDAA), Merano, Italy; H.-P. Hartung, Department of Neurology, Heinrich-Heine University, Dusseldorf, Germany and Brain and Mind Center, University of Sydney, Sydney, Australia.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Kang, C. Ravulizumab: A Review in Generalised Myasthenia Gravis. Drugs 83, 717–723 (2023). https://doi.org/10.1007/s40265-023-01877-6
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-023-01877-6